Alpha 1 acid glycoprotein (AGP) binds to STI571 and substantially alters its pharmacokinetics in chronic myeloid leukemia (CML) patients.

被引：0
|
作者：
Gambacorti-Passeri, C
Zucchetti, M
Frapolli, R
Russo, D
Rossi, F
Pogliani, E
Corneo, G
Tornaghi, L
Alberti, D
D'Incalci, M
机构：
[1] NCI, Milan, Italy
[2] Osped San Gerardo, Monza, Italy
[3] Mario Negri Inst Pharmacol Res, Milan, Italy
[4] Univ Udine, I-33100 Udine, Italy
[5] Novards Italia, Origgio, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1305
引用
收藏
页码：309A / 309A
页数：1
相关论文
共 50 条
  • [1] Alpha 1 acid glycoprotein (AGP) binds to STI571 and alters its tissue distribution and intracellular concentrations.
    Gambacorti-Passerini, C
    Zucchetti, M
    Cleris, L
    Rossi, F
    Pogliani, E
    Corneo, G
    Formelli, F
    D'Incalci, M
    BLOOD, 2000, 96 (11) : 98A - 98A
  • [2] α1 acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
    Gambacorti-Passerini, C
    Zucchetti, M
    Russo, D
    Frapolli, R
    Verga, M
    Bungaro, S
    Tornaghi, L
    Rossi, F
    Pioltelli, P
    Pogliani, E
    Alberti, D
    Corneo, G
    D'Incalci, M
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 625 - 632
  • [3] Treatment with STI571 (Novartis®) in chronic myeloid leukemia (CML):: Unexpected hematological findings in a series of 26 patients.
    Meunier, V
    Giraudier, S
    Van den Akker, J
    Perot, C
    Jouault, H
    Caron-Servan, B
    Robin, V
    Tulliez, M
    Imbert, M
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [4] Treatment of chronic myeloid leukemia (CML) with STI571 in patients age ≥60 years.
    Cortes, J
    Talpaz, M
    O'Brien, SM
    Manero, G
    Thomas, D
    Faderl, S
    Capdeville, R
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 256B - 256B
  • [5] Imatinib (STI571) therapy of chronic phase chronic myeloid leukemia (CML) resistant or intolerant to interferon:: Results in 134 patients.
    Cervantes, F
    Hernández-Boluda, JC
    Steegmann, JL
    Villalón, L
    Alvarez-Larrán, A
    Granda, A
    Martínez-Ruiz, F
    López-Jiménez, J
    Aláez, C
    García-Conde, J
    Montserrat, E
    Odriozola, J
    BLOOD, 2002, 100 (11) : 318B - 318B
  • [6] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [7] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [8] Determination of α-1 acid glycoprotein in patients with Ph plus chronic myeloid leukemia during the first 13 weeks of therapy with STI571
    le Coutre, P
    Kreuzer, KA
    Na, IK
    Lupberger, J
    Holdhoff, M
    Appelt, C
    Schwarz, M
    Müller, C
    Gambacorti-Passerini, C
    Platzbecker, U
    Bonnet, R
    Ehninger, G
    Schmidt, CA
    BLOOD CELLS MOLECULES AND DISEASES, 2002, 28 (01) : 75 - 85
  • [9] Elevated levels of the plasma glycoprotein, alpha-1-acid glycoprotein (AGP) in patients with CML should not mediate resistance to STI-571.
    Jorgensen, H
    Allan, E
    Elliott, M
    Holyoake, T
    Smith, K
    BLOOD, 2000, 96 (11) : 346A - 346A
  • [10] α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571
    Jorgensen, HG
    Elliott, MA
    Allan, EK
    Carr, CE
    Holyoake, TL
    Smith, KD
    BLOOD, 2002, 99 (02) : 713 - 715
12345